Print selected from Online session21/11/2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 27  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 28  Oct 21  EVENTLINE has been reloaded
 NEWS 29  Oct 24  BEILSTEIN adds new search fields
 NEWS 30  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 31  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 32  Nov 18  DKILIT has been renamed APOLLIT

 NEWS EXPRESS  October 14 CURRENT WINDOWS VERSION IS V6.01,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

Print selected from Online session13:33Page 1

Print selected from Online session21/11/2002

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:30:47 ON 21 NOV 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:31:00 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2
DICTIONARY FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10066503.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=>  sl1
SL1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1
SAMPLE SEARCH INITIATED 13:31:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    498 TO ITERATE

100.0% PROCESSED     498 ITERATIONS                              8 ANSWERS
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         8622 TO    11298
PROJECTED ANSWERS:               8 TO      329

L2             8 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 13:31:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  10264 TO ITERATE

100.0% PROCESSED   10264 ITERATIONS                            106 ANSWERS
SEARCH TIME: 00.00.05

L3           106 SEA SSS FUL L1

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   140.28     140.49

FILE 'USPATFULL' ENTERED AT 13:31:37 ON 21 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:31:37 ON 21 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

Print selected from Online session21/11/2002

```
=>  sl3
SL3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3
L4            2 L3

=> d a bs bib hitstr 1-2
'A' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
'BS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
```

Print selected from Online session21/11/2002

IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
without answer number. SCAN must be entered on the
same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d abs bib hitstr 1-2

L4 ANSWER 1 OF 2 USPATFULL
AB Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: ##STR1##

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: ##STR2##

where q is 1, 2, or 3, W.sup.3 is --O--; --N(R.sup.9)--; or --OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6) alkyl, --(C.sub.2-C.sub.6) alkenyl, or --(C.sub.2-C.sub.6) alkynyl substituted by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl;

pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is --O--; --S(.dbd.O).sub.t--, where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--, or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4) alkynyl; --R.sup.16; --OR.sup.16; --S(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.sup.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.16R.sup.16; --NR.sup.12.sub.aC(.dbd.N--NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17 --S(.dbd.O).sub.pNR.sup.16R.sup.17; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4) alkyl including dimethyl and --(C.sub.1-C.sub.4) alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2) alkoxycarbonyl-, (C.sub.1-C.sub.2) alkylcarbonyl-, or (C.sub.1-C.sub.2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): ##STR3##

or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:206794 USPATFULL

TI Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes

IN Magee, Thomas Victor, Mystic, CT, UNITED STATES
Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert James, Mystic, CT, UNITED STATES

PA Pfizer Inc. (U.S. corporation)

PI US 2002111495 A1 20020815

AI US 2002-62811 A1 20020131 (10)

PRAI US 2001-265240P 20010131 (60)
US 1997-43403P 19970404 (60)
US 1998-105120P 19981021 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7710

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **214754-96-8P 214754-98-0P 214755-00-7P**
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 214754-96-8 USPATFULL

CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214754-98-0 USPATFULL
CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 214755-00-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 USPATFULL
AB A compound of formula (I) wherein m, n, o, p, q, r, A, B, D, E, R.sup.1, R.sup.2,R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the description, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

Print selected from Online session21/11/2002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:95811 USPATFULL
TI Nicotinamide derivatives
IN Marfat, Anthony, Mystic, CT, United States
Chambers, Robert J., Mystic, CT, United States
Watson, John W., Ledyard, CT, United States
Cheng, John B., Waterford, CT, United States
Duplantier, Allen J., Ledyard, CT, United States
Kleinman, Edward F., Pawcatuck, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6380218 B1 20020430
WO 9845268 19981015
AI US 1999-308956 19990527 (9)
WO 1998-IB315 19980310
19990527 PCT 371 date
PRAI US 1997-43403P 19970404 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Richardson, Peter C., Ginsburg, Paul H., Speer, Raymond M.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **214754-96-8P 214754-98-0P 214755-00-7P**
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)
RN 214754-96-8 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214754-98-0 USPATFULL
CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)





RN 214755-00-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(3-pyridinyloxy)-
(9CI) (CA INDEX NAME)



=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.69	158.18

FILE 'CAPLUS' ENTERED AT 13:32:58 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Nov 2002 VOL 137 ISS 21
FILE LAST UPDATED: 20 Nov 2002 (20021120/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please

Print selected from Online session21/11/2002

check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L5 4 L3

=> d abs bib fhitstr

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd.

as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

AN 2002:594842 CAPLUS
DN 137:154859
TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060896	A1	20020808	WO 2001-IB2726	20011224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-265304P P 20010131
OS MARPAT 137:154859
IT **445294-90-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE4 isoenzyme inhibitor; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)
RN 445294-90-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d abs bib fhitstr 2-4

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

AN 2002:591707 CAPLUS
DN 137:140509
TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
IN Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1229034	A1	20020807	EP 2002-250202	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002111495	A1	20020815	US 2002-62811	20020131
	BR 2002000250	A	20021008	BR 2002-250	20020131
PRAI	US 2001-265240P	P	20010131		
	US 1997-43403P	P	19970404		
	US 1998-105120P	P	19981021		

OS MARPAT 137:140509
IT **444807-21-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
RN 444807-21-0 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH2, O, NH, SO, SO2, S; R1 is H, alkyl, cycloalkyl, aryl, etc.; R2,R3 together with attached carbon form carbonyl group or cycloalkyl ring; R2, R3, R4 is independently H, OH, CN, CO2H, alkyl, etc.; R5 is cyclic, bicyclic, aryl; R6, R7 and R8 are each independently H, CN, COOH, NO2, OH, alkyl, etc.] and pharmaceutical compn. are prepd. for the treatment of respiratory, allergic, rheumatoid, body wt. regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, wt. control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

AN 1998:682365 CAPLUS

DN 129:316147

TI Preparation of nicotinamides as PDE4 D isoenzymes inhibitors

IN Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob; Kleinman, Edward Fox

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845268	A1	19981015	WO 1998-IB315	19980310
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9862273	A1	19981030	AU 1998-62273	19980310
	AU 738037	B2	20010906		
	EP 971894	A1	20000119	EP 1998-904343	19980310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2000510481	T2	20000815	JP 1998-542528	19980310
	BR 9810733	A	20000912	BR 1998-10733	19980310
	ZA 9802853	A	19991004	ZA 1998-2853	19980403
	US 6380218	B1	20020430	US 1999-308956	19990527
	NO 9904791	A	19991201	NO 1999-4791	19991001

	US 2002111495	A1	20020815	US 2002-62811	20020131
PRAI	US 1997-43403P	P	19970404		
	WO 1998-IB315	W	19980310		
	US 1998-105120P	P	19981021		
	US 2001-265240P	P	20010131		

OS MARPAT 129:316147

IT **214754-96-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 214754-96-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

GI



I



II



III

AB The title compds. [I; R1 = alkyl; R2 = (halo)alkyl; R3 = H, halo; R4-R6 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R7, R8 = H, (substituted) alkyl, Ph, R7R8N = 3-9-membered heterocycle] are prepd. and formulated. Pyrazole deriv. II (1.3 g) was stirred with KOH in MeOH at room temp., MeOH was distd., toluene was added and distd., the remaining solid was heated with 1.0 g chloropyridine deriv. III and 0.01 g CuCl in DMF at 110.degree. to

give 0.80 g I (R1 = Me, R2 = 3-CF3, R3-R7 = H, R8 = 6-CH2CF3), which controlled >90% barnyard grass, Setaria viridis, etc. at 2.5 kg/ha.

AN 1996:132822 CAPLUS
DN 124:176091
TI Preparation of (pyridyloxy)pyrazole derivatives as herbicides
IN Morimoto, Katsuyuki; Oonari, Masatoshi; Furusawa, Hiroyuki; Hatanaka, Masataka; Watanabe, Junichi; Kondo, Yasuo; Nawamaki, Tsutomu; Ishikawa, Kimihiro; Shiojima, Kenichi; Nakahira, Kunimitsu
PA Nissan Chemical Ind Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07285962	A2	19951031	JP 1994-81585	19940420

OS MARPAT 124:176091
IT **173946-99-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (pyridyloxy)pyrazole derivs. as herbicides)
RN 173946-99-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)